Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040257 | 0.94 | AHR (0.33) | HRH3MAOBBCHEMAOAACHE | |
| SCHEMBL4035884 | 0.87 | CACNA1H (0.36) | HRH3MAOBBCHEMAOAACHE | |
| Hydrochloric Acid SCHEMBL4038349 | 0.86 | CACNA1H (0.35) | HRH3MAOBBCHEMAOAACHE | |
| SCHEMBL4037140 | 0.84 | MAPK1 (0.36) | HRH3MAOAACHEKDM4E | |
| SCHEMBL5414669 | 0.84 | HTR1B (0.38) | HRH3KDM4EALDH1A1MAPTHTR1B | |
| SCHEMBL5425097 | 0.81 | CACNA1H (0.35) | HRH3MAOBBCHEMAOAACHE | |
| SCHEMBL5417751 | 0.81 | SLC6A4 (0.32) | MAOBBCHEMAOAACHE | |
| SCHEMBL4043579 | 0.80 | HDAC3 (0.41) | HRH3MAOBBCHEMAOAACHE | |
| SCHEMBL4046594 | 0.80 | CYP1A2 (0.35) | MAOBBCHEMAOAACHECACNA1H | |
| SCHEMBL4042515 | 0.80 | ALDH1A1 (0.37) | MAOBBCHEMAOAACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284977-B1 | THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-24 | — | — | EP | claimed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | claimed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | claimed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | claimed |
| JP-2009102513-A | POLYMER, COMPOSITION, CURED MATERIAL, AND OPTICAL RECORDING MEDIUM | MITSUBISHI CHEMICALS CORP | 2009-05-14 | — | — | JP | disclosed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | disclosed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | disclosed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | HRH3 2531/4885MAOB 1706/4885BCHE 433/4885 |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | HRH3 2562/4885MAOB 1752/4885BCHE 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.